(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.27%) $79.16
(-0.69%) $2.02
(0.04%) $2 310.50
(0.19%) $26.88
(0.50%) $967.40
(-0.09%) $0.931
(-0.14%) $10.98
(-0.18%) $0.796
(1.50%) $92.50
-6.96% $ 4.41
@ $5.09
Wydano: 14 vas. 2024 @ 16:30
Zwrot: -13.36%
Poprzedni sygnał: vas. 12 - 20:37
Poprzedni sygnał:
Zwrot: -0.97 %
Live Chart Being Loaded With Signals
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS)...
Stats | |
---|---|
Dzisiejszy wolumen | 317 012 |
Średni wolumen | 263 427 |
Kapitalizacja rynkowa | 119.18M |
EPS | $0 ( 2024-02-13 ) |
Następna data zysków | ( $-0.340 ) 2024-06-26 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.490 |
ATR14 | $0.0110 (0.25%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Rotunno Mary L. | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Gin Jerry B | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Fitzpatrick Margaret M | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Curley Joanne | Buy | 12 500 | Stock Option (Right to Buy) |
2024-03-04 | Cunningham Ann Michelle | Buy | 12 500 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
98.65 |
Last 94 transactions |
Buy: 11 348 392 | Sell: 716 774 |
Wolumen Korelacja
VistaGen Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ADXN | 0.836 |
SHYF | 0.828 |
SRRK | 0.827 |
FLUX | 0.822 |
PRAX | 0.821 |
LILAK | 0.819 |
LILA | 0.816 |
PXLW | 0.816 |
TNXP | 0.816 |
FOXA | 0.805 |
10 Najbardziej negatywne korelacje | |
---|---|
FEYE | -0.808 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
VistaGen Therapeutics Inc Korelacja - Waluta/Towar
VistaGen Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $-227 300 |
Zysk brutto: | $-737 100 (324.29 %) |
EPS: | $-8.51 |
FY | 2023 |
Przychody: | $-227 300 |
Zysk brutto: | $-737 100 (324.29 %) |
EPS: | $-8.51 |
FY | 2022 |
Przychody: | $1.11M |
Zysk brutto: | $293 700 (26.49 %) |
EPS: | $-7.24 |
FY | 2021 |
Przychody: | $1.09M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.208 |
Financial Reports:
No articles found.
VistaGen Therapeutics Inc
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej